Pyruvate kinase M2-specific siRNA induces apoptosis and tumor regression

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Cancer cells often rely on common metabolic pathways with healthy cells, limiting the development of targeted therapies.
• Pyruvate kinase M2 (PKM2) isoform is upregulated in cancer cells, promoting aerobic glycolysis and conferring a growth advantage.
• Inhibiting PKM2 may offer broad applicability for cancer treatment due to common oncogene-driven metabolic alterations.

Purpose of the Study:

• To investigate the potential of targeting the PKM2 isoform for cancer therapy.
• To develop isoform-specific small interfering RNAs (siRNAs) for PKM2 knockdown.
• To evaluate the efficacy of siPKM2 in reducing cancer cell viability and inducing apoptosis in vitro and in vivo.

Main Methods:

• Design and synthesis of small interfering RNAs (siRNAs) specifically targeting PKM2.
• Assessment of siRNA-mediated knockdown in various cancer cell lines and normal cells.
• Evaluation of cell viability and apoptosis assays.
• In vivo studies using xenograft models to assess tumor regression.

Main Results:

• siRNAs designed to target PKM2 specifically reduced its expression in cancer cells.
• PKM2 knockdown led to decreased viability and increased apoptosis in multiple cancer cell lines.
• Normal fibroblasts and endothelial cells showed less sensitivity to siPKM2.
• In vivo administration of siPKM2 resulted in significant regression of established tumors.

Conclusions:

• Isoform-specific targeting of PKM2 using siRNA is a viable strategy for cancer therapy.
• siPKM2 demonstrates efficacy in reducing cancer cell proliferation and inducing cell death.
• The nucleotide-level specificity of siRNA can be leveraged to develop therapeutics targeting differentially spliced gene isoforms.